Vertex Pharmaceuticals (NASDAQ: VRTX), a leading drugmaker, is performing exceedingly well for the year -- or at least it was ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Princeton University awarded honorary degrees to Omar M. Yaghi, Daniel Chee Tsui, Nancy Weiss Malkiel, Joshua ...

To access the call, please dial (833) 630-2124 (U.S.) or +1(412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2025 Earnings Call.” The conference call will ...

For the second quarter of 2025, Vertex projects revenues between $182 million and $187 million, with adjusted EBITDA ranging from $35.5 million to $39.5 million. For the full year, the company ...

After a rough start to the year, small- and mid-cap software stocks may be finding their footing. Goldman Sachs analyst Adam ...

Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF) patients could benefit from treatment for the first time. The company is a pioneer in ...

to start this year — BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (VRTX) today reported consolidated financial results for the first quarter ended March 31, 2025, and raised the ...

Since launch through May 1st, Vertex has activated more than 65 authorized treatment centers (ATCs) globally and approximately 90 patients have had their first cell collection. Vertex recently ...

“Vertex continued to perform well in the first quarter, setting us up for a strong 2025,” said David DeStefano, Vertex’s President, Chief Executive Officer and Chairperson of the Board.